1Head & Neck Cancer Interdisciplinary Team, The Catholic University of Korea College of Medicine, Seoul, Korea.
2Department of Diagnostic Radiology, The Catholic University of Korea College of Medicine, Seoul, Korea.
3Department of Nuclear Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.
4Department of Hospital Pathology, The Catholic University of Korea College of Medicine, Seoul, Korea.
5Department of Radiation Oncology, The Catholic University of Korea College of Medicine, Seoul, Korea.
6Department of Otorhinolaryngology, The Catholic University of Korea College of Medicine, Seoul, Korea.
7Department of Medical Oncology, The Catholic University of Korea College of Medicine, Seoul, Korea.
Copyright © 2008 Korean Cancer Association
Patient characteristics
*AJCC 2002 staging system, †non-significant.
Antitumor efficacy; Response after concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy (AC)
*complete response, †partial response, ‡stable disease, §progressive disease.
Acute toxicity during concurrent chemoradiotherapy
Acute toxicity during adjuvant chemotherapy
*AJCC 2002 staging system, †non-significant.
*complete response, †partial response, ‡stable disease, §progressive disease.